Skip to content

Advertisement

Critical Care

Open Access

Clinical solutions: not always what they seem?

Critical Care201519:213

https://doi.org/10.1186/s13054-015-0870-4

Published: 7 May 2015

Keywords

Intensive Care UnitSeptic ShockPeritoneal DialysisClinical CareDextrose

Brenner and colleagues [1], in their article published in Critical Care, showed elevated levels of the reactive carbonyl species (RCS) methylglyoxal (MG) in the circulation of patients with septic shock. We commend the authors’ bravery in launching this molecule into a field well-populated with biomarkers and where clinical diagnosis persists as the ‘gold standard’ [2].

The authors hypothesised that MG accumulation resulted from metabolic dysregulation and oxidative stress associated with septic shock. Impairment of MG detoxification was also proposed as a contributory factor. However, whether MG was, at least in part, inadvertently administered during routine clinical care appears not to have been considered.

Some clinical solutions, such as peritoneal dialysis fluid, are known to contain MG and other RCS [3,4]. Bearing in mind that patients with septic shock, managed on intensive care units, typically receive large volumes of intravenous fluids and, in due course, enteral (and parenteral) nutrition, could these solutions not also be a source of MG and other RCS? Also, 25% of the septic shock patients in Benner and colleagues’ study [1] had acute liver failure, and such patients often require infusions of high concentration dextrose, a further potential source of RCS. Given the growing awareness that clinical solutions are not always what they seem, we would suggest that measurements of MG and other RCS levels in solutions administered to patients with sepsis could be a helpful and perhaps an illuminative and valuable addition not only to this study but to the sepsis shock/intensive care field in general.

Notes

Abbreviations

MG: 

Methylglyoxal

RCS: 

Reactive carbonyl species

Declarations

Authors’ Affiliations

(1)
Vascular Biology, Cardiovascular Sciences, National Heart and Lung Institute Division, Faculty of Medicine, Imperial College London, London, UK
(2)
Intensive Care and Respiratory Medicine, The Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK
(3)
Surrey Perioperative Anaesthesia and Critical care collaborative Research group (SPACeR), Faculty of Health and Medical Science, Duke of Kent Building, University of Surrey, Guildford, UK

References

  1. Brenner T, Fleming T, Uhle F, Silaff S, Schmitt F, Salgado E, et al. Methylglyoxal as a new biomarker in patients with septic shock: an observational clinical study. Crit Care. 2014;18:683.View ArticlePubMed CentralPubMedGoogle Scholar
  2. Prucha M, Bellingan G, Zazula R. Sepsis biomarkers. Clin Chim Acta. 2015;440c:97–103.View ArticleGoogle Scholar
  3. Hirahara I, Kusano E, Yanagiba S, Miyata Y, Ando Y, Muto S, et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int. 2006;26:380–92.PubMedGoogle Scholar
  4. Inagi R, Miyata T, Ueda Y, Yoshino A, Nangaku M, van Ypersele Strihou de C, et al. Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid. Kidney Int. 2002;62:679–87.View ArticlePubMedGoogle Scholar

Copyright

© Burke-Gaffney and Creagh-Brown; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement